An affordable new BRCA gene test has hit the market, but who should take it? — -- A new genetic testing kit that hits the market today is the most affordable, and arguably one of the simplest, ...

As technology improves, Columbus-area doctors say more patients are undergoing testing to see if they have an elevated risk ...

ROANOKE, Va. – It’s estimated that more than 42,000 people will die from breast cancer this year, according to the American Cancer Society. To help you understand if you’re at a greater risk of ...

Harmful variants in the BRCA1 gene greatly increase a person’s lifetime risk of developing breast, ovarian and pancreatic cancers, but most people are unaware they are carriers. In a new study in the ...

Since the NHS Jewish BRCA Testing Programme began in January 2023, around 11,000 saliva tests have been processed, with 235 people (2.1%) testing positive for a BRCA gene mutation, according to new ...

In this video, I share my experience of discovering I carry the BRCA1 gene, prompted by my mum’s history with breast cancer. I talk about taking the genetic test myself, the steps that led to my ...

Carla Peoples thought her symptoms were due to another problem, but was shocked to be diagnosed with ovarian cancer. She ...

ASCO and the Society of Surgical Oncology (SSO) recently published a joint guideline to provide formal consensus-based recommendations on the role of germline mutation testing in patients with breast ...

Phase III Double-Blind Study of Glutamine Versus Placebo for the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy Conclusion: In a clinical setting, we show a high demand ...

SEATTLE — The BRCA gene is commonly recognized for its link to breast and ovarian cancer risk among women. Mutations in BRCA1 and BRCA2 have been associated with increased risk for the cancers, but ...

Patients with ovarian cancer who undergo BRCA testing face higher health care resource utilization (HCRU) and costs but are more likely to receive genomically targeted therapies and progress to later ...

Lynparza significantly improves iDFS, DDFS, and OS in BRCA1/2 mutation-positive, HER2-negative high-risk breast cancer patients. The trial's six-year analysis shows consistent benefits across all ...